Does Ozempic cause stomach pain? Yes, abdominal pain is a recognised and common side effect of Ozempic (semaglutide), a GLP-1 receptor agonist used to treat type 2 diabetes in the UK. Gastrointestinal symptoms—including nausea, abdominal discomfort, bloating, and altered bowel habits—occur because Ozempic slows gastric emptying and affects gut motility. Whilst these effects are usually mild to moderate and often improve over time, understanding why they occur, how to manage them, and when to seek medical advice is essential for safe and effective treatment. This article provides evidence-based guidance aligned with UK clinical practice and MHRA-approved prescribing information.

Understanding Ozempic and Gastrointestinal Side Effects

Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus. It works by mimicking the action of naturally occurring GLP-1, a hormone that regulates blood glucose levels by stimulating insulin secretion, suppressing glucagon release, and slowing gastric emptying. Administered as a once-weekly subcutaneous injection, Ozempic has demonstrated significant efficacy in improving glycaemic control in clinical trials. While weight loss may occur during treatment, it's important to note that Ozempic is not licensed for weight management in the UK (Wegovy is the brand of semaglutide licensed specifically for weight management).

Gastrointestinal side effects are among the most frequently reported adverse reactions associated with Ozempic therapy. According to the MHRA-approved Summary of Product Characteristics (SmPC), nausea is very common (affecting more than 1 in 10 people), while abdominal pain, vomiting, diarrhoea, and constipation are common (affecting between 1 in 100 and 1 in 10 people). These effects are associated with the drug's mechanism of action on the gastrointestinal tract.

The slowing of gastric emptying—whilst therapeutically beneficial for glucose control and satiety—can lead to feelings of fullness, bloating, and abdominal discomfort. For many patients, these symptoms are mild to moderate in severity and tend to diminish over time as the body adapts to the medication. However, understanding why these effects occur and how to manage them is essential for treatment adherence and patient wellbeing.

It is important to note that whilst stomach pain is a recognised side effect of Ozempic, not all abdominal discomfort experienced during treatment is necessarily caused by the medication. Other gastrointestinal conditions, including gallbladder disease (cholelithiasis or cholecystitis), may coincide with therapy. Persistent or severe symptoms warrant proper clinical evaluation to exclude alternative diagnoses.

Why Does Ozempic Cause Stomach Pain?

The stomach pain associated with Ozempic use stems primarily from its pharmacological action on the gastrointestinal system. As a GLP-1 receptor agonist, semaglutide binds to GLP-1 receptors located throughout the gut, pancreas, and central nervous system. Activation of these receptors in the gastrointestinal tract results in delayed gastric emptying—the rate at which food moves from the stomach into the small intestine is significantly reduced.

This delayed emptying means that food remains in the stomach for longer periods, which can cause sensations of fullness, bloating, upper abdominal discomfort, and cramping. The stomach may feel distended or uncomfortably full even after consuming smaller portions than usual. Some patients describe a sensation of pressure or heaviness in the epigastric region (upper central abdomen).

Additionally, GLP-1 receptor activation affects gastrointestinal motility more broadly, potentially leading to altered bowel habits. Constipation—another common side effect—can contribute to lower abdominal pain and cramping. Conversely, some patients experience diarrhoea, which may cause colicky abdominal pain and urgency.

The nausea frequently reported with Ozempic can also be accompanied by stomach discomfort. This occurs partly due to delayed gastric emptying and partly through central nervous system effects, as GLP-1 receptors in the brainstem influence nausea and satiety signals.

It is worth noting that the intensity of these gastrointestinal effects is often dose-dependent. According to the UK SmPC, Ozempic is typically initiated at 0.25 mg weekly for four weeks, then increased to 0.5 mg weekly, with potential further escalation to 1 mg weekly and then 2 mg weekly if needed for additional glycaemic control and if tolerated. The gradual dose titration recommended in prescribing guidance aims to minimise gastrointestinal side effects by allowing the body time to adapt to the medication's effects on gut motility. Unlike oral medications, injectable semaglutide can be administered irrespective of meals.

How Common Is Stomach Pain with Ozempic?

Gastrointestinal adverse effects are common with Ozempic therapy. According to the UK SmPC, nausea is classified as very common (affecting ≥1/10 patients), making it one of the most frequently reported side effects. Abdominal pain is classified as common (affecting ≥1/100 to <1/10 patients).

In the pivotal SUSTAIN clinical trial programme, which evaluated semaglutide across various doses and patient populations, the frequency of gastrointestinal symptoms varied by dose. The MHRA-approved SmPC reports that abdominal pain occurred in approximately 7-10% of participants receiving the 0.5 mg dose and 5-11% of those on the 1 mg dose. Nausea was reported in up to 20% of patients in some trials, and diarrhoea affected approximately 8-12% of participants.

Importantly, the temporal pattern of these side effects is clinically relevant. Gastrointestinal symptoms, including stomach pain, typically emerge during the initial weeks of treatment or following dose escalation. For most patients, these effects are transient, with the greatest intensity occurring in the first 4-8 weeks of therapy. As treatment continues, many individuals experience a gradual reduction in symptom severity as physiological adaptation occurs.

However, a minority of patients experience persistent gastrointestinal symptoms that do not adequately resolve over time. In clinical trials, discontinuation rates due to gastrointestinal adverse effects ranged from 3-7%, indicating that whilst most patients can tolerate these symptoms, they can be sufficiently troublesome to necessitate treatment cessation in some cases.

Real-world data from post-marketing surveillance and patient registries generally align with clinical trial findings, confirming that stomach pain and related gastrointestinal effects are among the most common reasons patients contact their healthcare providers during Ozempic therapy. Understanding this frequency helps set realistic expectations and emphasises the importance of appropriate patient counselling before initiating treatment.

Managing and Reducing Stomach Pain on Ozempic

Effective management of stomach pain whilst taking Ozempic involves a combination of dietary modifications, lifestyle adjustments, and appropriate use of symptomatic treatments. These strategies can significantly improve tolerability and support treatment adherence.

Dietary modifications are often the most effective first-line approach:

• Eat smaller, more frequent meals rather than large portions, as this reduces the burden on delayed gastric emptying

• Avoid high-fat foods, which are slower to digest and may exacerbate feelings of fullness and discomfort

• Reduce intake of spicy, acidic, or heavily seasoned foods that may irritate the gastrointestinal tract

• Limit carbonated beverages, which can increase bloating and abdominal distension

• Eat slowly and chew thoroughly to aid digestion and reduce the volume of air swallowed

• Stay well hydrated, particularly if experiencing diarrhoea, but avoid drinking large volumes with meals

Timing considerations can also help. Some patients find that administering their weekly Ozempic injection on the same day each week, preferably when they can rest if needed, helps them manage any temporary increase in symptoms. Consistent once-weekly dosing is important, and injectable semaglutide can be administered irrespective of meals.

For constipation-related abdominal pain, increasing dietary fibre gradually, maintaining adequate hydration, and engaging in regular physical activity can be beneficial. If these measures are insufficient, bulk-forming laxatives such as ispaghula husk or osmotic laxatives like macrogol may be appropriate, following discussion with a GP or pharmacist.

Patients should always consult their pharmacist or GP before starting any over-the-counter remedies to ensure compatibility with their diabetes treatment regimen. Antacids may help with upper abdominal discomfort related to acid reflux, whilst antispasmodics may ease cramping pain in some cases.

Patients taking Ozempic alongside insulin or sulfonylureas should monitor their blood glucose more frequently if nausea or vomiting reduces their food intake, as there may be an increased risk of hypoglycaemia. Seek advice from your diabetes care team about potential dose adjustments of these medications if needed.

If stomach pain persists despite these measures, discussing dose adjustment with the prescribing clinician may be appropriate. Some patients benefit from a slower titration schedule or temporarily pausing dose escalation if glycaemic targets are being met. The decision to adjust dosing should always be made in consultation with a healthcare professional, balancing symptom management with therapeutic efficacy.

When to Seek Medical Advice About Stomach Pain

Whilst mild to moderate stomach pain is a recognised side effect of Ozempic, certain symptoms warrant prompt medical evaluation to exclude serious complications or alternative diagnoses.

Seek urgent medical attention (contact 999 or attend A&E) if experiencing:

• Severe, persistent abdominal pain, particularly if it is constant and worsening

• Signs of pancreatitis: severe upper abdominal pain radiating to the back, often accompanied by nausea and vomiting

• Symptoms of bowel obstruction: severe abdominal pain with inability to pass stool or wind, progressive abdominal distension, and persistent vomiting

• Signs of dehydration: dizziness, reduced urine output, extreme thirst, or confusion, particularly if associated with severe vomiting or diarrhoea

• Blood in vomit or stool, which may indicate gastrointestinal bleeding

• Signs of gallbladder disease: severe right upper quadrant pain (which may be accompanied by fever), pain after fatty meals, or jaundice (yellowing of the skin or eyes)

Contact your GP or diabetes specialist nurse within 24-48 hours if:

• Stomach pain persists beyond the first few weeks of treatment without improvement

• Abdominal discomfort is significantly affecting your quality of life or ability to eat adequately

• You are unable to maintain hydration or nutrition due to gastrointestinal symptoms

• New symptoms develop, such as jaundice (yellowing of skin or eyes), dark urine, or pale stools

• You experience unexplained weight loss beyond what is expected with diabetes management

Pancreatitis is a rare but serious adverse effect associated with GLP-1 receptor agonists, including Ozempic. The UK SmPC includes a specific warning about this risk. If pancreatitis is suspected, Ozempic should be discontinued immediately and urgent medical assessment sought.

Gallbladder disease (including cholelithiasis and cholecystitis) has been reported in patients taking GLP-1 receptor agonists, particularly in the context of rapid weight loss. Be alert to symptoms such as right upper quadrant pain, fever, or jaundice.

It is also important to remember that not all abdominal pain during Ozempic therapy is caused by the medication. Other gastrointestinal conditions—including peptic ulcer disease, gallstones, irritable bowel syndrome, or inflammatory bowel disease—may coincide with treatment. Persistent or atypical symptoms should be properly investigated to ensure appropriate diagnosis and management.

Regular follow-up with your diabetes care team is essential to monitor both the efficacy and tolerability of Ozempic therapy, allowing for timely adjustments to optimise your treatment plan whilst maintaining safety.

If you experience any suspected side effects from Ozempic, you can report them directly to the MHRA through the Yellow Card Scheme (yellowcard.mhra.gov.uk). This helps the MHRA monitor the safety of medicines.

Frequently Asked Questions